00
Days
00
Hours
00
Minutes
00
Seconds

43rd Annual Meeting

Annual Meeting Theme:
Informing Public Health Policy with Compelling Evidence

When

May 15-18, 2022

Where

San Diego, CA, USA

Registration

Now Open!

The Conference Venue

San Diego Hilton Bayfront Hotel

Alluring and inspired by maritime culture, the distinctive coastal influence is clear the moment you arrive at our 30-story waterfront hotel. Featuring newly renovated guest rooms that are authentically San Diego in their design. Our hotel is conveniently located adjacent to the San Diego Convention Center, and across the Harbor Drive Pedestrian Bridge from the Padres' Petco Park and Downtown Gaslamp Quarter.

Registration is Now Open

Meeting | Overview

About the Annual Meeting
The Annual Meeting of the Society for Clinical Trials is a multidisciplinary program with broad participation. The Meeting brings together the clinical trials community from academia, the pharmaceutical and device industries, government agencies, medical groups and centers and clinical research entities.

Highlights include:

  • Plenary sessions, topical sessions and contributed presentations (both live and on-demand) on COVID-19 studies, the impact of COVID-19 on trials, along with many other clinical trial related topics
  • In-conference educational workshops, offering guidance on both classical and topical issues in clinical trials
  • Annual Thomas C. Chalmers Student Scholarship and Sylvan Green Award competitions
  • Discussion of timely issues and research experiences among colleagues in the field of clinical trials
  • Presentation of the 2021 David Sackett Trial of the Year Award
  • Presentation of the SCT Class of 2022 Fellows

This year’s meeting will be San Diego, CA, USA.

The program is being developed by the SCT Program and Education Committees, and promises to make the best of this unique opportunity for global collaboration.

We look forward to welcoming you!

About the Society
The Society for Clinical Trials (SCT) is an educational, charitable, and scientific organization whose mission is to work internationally to advance human health through advocating the use of clinical trials, leading the development and dissemination of optimal methods and practices in clinical trials, and educating and developing all clinical trial professionals. We are a society with representation from academia, industry, government and non-profit research and advocacy groups. Our community consists of clinical investigators, biostatisticians, project managers, IT specialists, clinical research associates and people from other clinical trials specialties. Our membership spans the globe with representation from 34 different countries.

Find out more: http://www.sctweb.org/

Registration | Pricing

 LIVE MEETING - REGISTER BY CREDIT CARD  LIVE MEETING - REGISTER BY CHECK
Live Meeting CATEGORY Member Non-Member Student (Member) Student (Non-Member)
Live Meeting Registration
   (Early-Bird Before April 4th)
   (Late After April 4th)
$595.00
$695.00
$820.00
$920.00
$150.00
$175.00
$225.00
$250.00
Roundtables (Monday 11:30-12:45) $25.00 $25.00 $0.00 $0.00
Workshop Pre-Conference Half-day
   (Early Bird Before April 4th)
   (Late After April 4th)
$200.00
$250.00
$250.00
$300.00
$75.00
$75.00
$75.00
$75.00
Workshop In-Conference $25.00 $25.00 $25.00 $25.00
VIRTUAL MEETING CATEGORY Member Non-Member Student (Member) Student (Non-Member)
 VIRTUAL MEETING Registration This option is to have online access via Zoom to virtual meeting events including:
  • Curtis Meinert Keynote Lecture
  • Annual Dave Sackett Trial of the Year Award
  • Thomas C. Chalmers Scholarship & Sylvan Green Award
  • Founders Keynote Lecture
  • Presentation Class of Fellows
  • Any other On-demand content that is created will be provided
   (Early Bird Before April 4th)
   (Late After April 4th)		 $300.00
$350.00 		$525.00
$575.00 		$150.00
$175.00 		$225.00
$250.00

Discounted Fees
Discounted fee available for attendees from developing countries. Please email registration@sctweb.org for more information about discounts or any other questions.

Registration Policy
All payments must be made in USD ($) to ensure that the full amount is received. Entry to the conference will not be permitted unless full payment has been received.

Cancellation Policy
Written cancellations received via email to registration@sctweb.org by May 2nd will be refunded less a $50 administrative fee. There will be no refunds issued after May 2nd. Failure to attend without notice will not result in a refund.

Program | At a Glance

We are delighted to release the provisional program for the 43rd annual meeting of the Society which will run May 15-18, 2022. The theme for the 43rd Annual Meeting is "Informing Public Health Policy with Compelling Evidence". The Program includes two exciting keynote talks, over 20 thematic sessions and over 100 contributed presentations on diverse topics. Contributors come from a wide range of backgrounds and disciples representing the range of stakeholders in clinical trial research and conduct. Clicking on the red icon will download session details where available. Please note that the program is not fully confirmed and speakers and timing particularly within individual sessions may be subject to some change. Note all times are Pacific.

Download SCT 2022 Program Guide (PDF)
Sunday, May 15, 2022
7:00 AM - 5:00 PM
  • REGISTRATION Indigo Light Wall (2nd Floor)
8:00 AM - 12:00 PM
  • PRE-CONFERENCE WORKSHOP 1 Indigo 202 B (2nd Floor)
       Improving Precision and Power in Randomized Trials by Leveraging Baseline Variables
  • PRE-CONFERENCE WORKSHOP 2 Indigo 202 A (2nd Floor)
       Clinical Trial Data Monitoring Committees and Reporting Statistical Centers: The Basics and Emerging Issues
  • PRE-CONFERENCE WORKSHOP 3 Indigo 204 B (2nd Floor)
       Model-Assisted Designs: Make Adaptive Clinical Trials Easy and Accessible
9:45 AM - 10:15 AM
  • BREAK
12:00 PM - 1:00 PM
  • LUNCH (ON YOUR OWN)
1:00 PM - 5:00 PM
2:45 PM - 3:15 PM
  • BREAK
5:00 PM - 6:45 PM
  • BOARD OF DIRECTORS MEETING
7:00 PM - 10:00 PM
  • FELLOWS DINNER LOCATION
    San Diego Hilton Bayfront Hotel Room 204A Level 2
Monday, May 16, 2022
7:00 AM - 5:00 PM
  • REGISTRATION Indigo Light Wall (2nd Floor)
8:00 AM - 9:30 AM
  • SCT PRESIDENT WELCOME Indigo BCFG (2nd Floor)
    Mithat Gönen, PhD | Memorial Sloan-Kettering Cancer Center
  • CURTIS MEINERT KEYNOTE LECTURE Indigo BCFG (2nd Floor)
    “Lessons Learned from the National Cancer Institute’s Community-Based Clinical Trials” | Dr. Worta McCaskill-Stevens
9:30 AM - 10:00 AM
10:00 AM - 11:30 AM
  • INVITED SESSION 1 Indigo D (2nd Floor)
      Optimizing Precision Medicine Cancer Clinical Trials
  • INVITED SESSION 2 Indigo E (2nd Floor)
      Inclusive Recruitment Strategies in Clinical Trials: Insights from Rehabilitation Research
  • INVITED SESSION 3 Indigo 202 A (2nd Floor)
      The Promise and Challenges of Integrating Real-World Evidence in Clinical Research
  • INVITED SESSION 4 Indigo H (2nd Floor)
      Real World Experience in Conducting Adaptive Platform Trials
  • INVITED SESSION 5 Indigo BCFG (2nd Floor)
      Strategies to Mitigate the Impact of the COVID Pandemic on Trial Implementation, Closeout, Data Quality and Analysis of a Large Multicenter Clinical Trial:
      The Glycemia Reduction Approaches in Diabetes Comparative Effectiveness Study (GRADE)
  • IN-CONFERENCE WORKSHOP 1 Indigo 202 B (2nd Floor)
      Behavioural Trial Design:
      Using Stakeholder-Driven Processes to Develop Interventions and Assessment Tools Using a Public Health Intervention Example
11:30 AM - 12:45 PM
  • LUNCH Indigo BCFG (2nd Floor)
  • ROUNDTABLE 1 Indigo Terrace (2nd Floor)
    DSMB
    Moderator: David DeMets, PhD
  • ROUNDTABLE 2 Indigo Terrace (2nd Floor)
    Introduction to Clinical Trial Career Paths + with Guest Attendee from Leadership
    (Members are encouraged to attend from diverse field backgrounds.)
    Moderator: Cristina Murray-Krezan
  • ROUNDTABLE 3 Indigo Terrace (2nd Floor)
    On Navigating Common Issues in Clinical Trials
    (e.g., protocol deviations, adverse events, ethical considerations) (Members are encouraged to attend from diverse field backgrounds.)
    Moderator: Julia Collins
  • ROUNDTABLE 4 Indigo Terrace (2nd Floor)
    How to Get Involved with SCT
    (This session will provide some background on the society and structure along with ideas for networking and professional growth within the society.)
    Moderator: Jody Ciolino, PhD
  • ROUNDTABLE 5 Indigo Terrace (2nd Floor)
    New Efficiencies & Lessons Learned in a Pandemic Time
    Moderator: Margaret Tiktin, DNP, CNP, MBA
  • ROUNDTABLE 6 Indigo Terrace (2nd Floor)
    Precision Trial Medicine
    Moderator: Pam Mangat
  • ROUNDTABLE 7 Indigo Terrace (2nd Floor)
    Supplemental Clinical Trial Data vs. Real World Data
    Moderator: Ben Ackerman, PhD
  • ROUNDTABLE 8 Indigo Terrace (2nd Floor)
    The Statistician as an Investigator and Educator, Not Just a Power Calculator, on Clinical Research Protocols
    Moderator: Alexia Iasonos, PhD
  • ROUNDTABLE 9 Indigo Terrace (2nd Floor)
    Fostering Equity, Diversity, and Inclusion within the Society
    Moderator: Kaleab Abebe, PhD
12:45 PM - 2:00 PM
  • CHALMERS AWARD FINALISTS Indigo BCFG (2nd Floor)
      Simultaneous Hypothesis Testing for Multiple Competing Risks in Comparative Clinical Trials
      Estimating Interactions and Subgroup-Specific Treatment Effects in Meta-Analysis Without Aggregation Bias: A Within-Trial Framework
      A Permutation Procedure to Detect Heterogeneous Treatments Effects in Randomized Clinical Trials While Controlling the Type-I Error Rate
  • SYLVAN GREEN AWARD WINNER Indigo BCFG (2nd Floor)
      Enhancing Patient-Partnership in Clinical Trials
12:45 PM - 2:15 PM
  • INVITED SESSION 6 Indigo 202 A (2nd Floor)
      Innovative Approaches to Data Collection Needs in Clinical Trials: Considerations, Lessons Learned and Future Directions
  • INVITED SESSION 7 Indigo D (2nd Floor)
      Complex Innovative Design in the Modern Drug Development Era
  • INVITED SESSION 9 Indigo H (2nd Floor)
      Analysing Clinical Trials Disrupted by the COVID-19 Pandemic
  • INVITED SESSION 10 Indigo E (2nd Floor)
      How Different Communication Pathways Impact the Success of a Clinical Trial, A Multifaceted Perspective
  • IN-CONFERENCE WORKSHOP 2 Indigo 202 B (2nd Floor)
      Causal Inference for Complex Data
2:15 PM - 2:30 PM
  • BREAK
2:30 PM - 3:30 PM
  • CONTRIBUTED SESSION 1 Indigo E (2nd Floor)
    Applied 1
      The Inclusion of Covariates in Constrained Longitudinal Data Analysis for Pre-Post Randomized Clinical Trials
      The Benefits of Covariate Adjustment for Adaptive Multi-Arm Designs
      TwinRCT: Leveraging External Data, Artificial Intelligence, and Covariate Adjustment
      Bayesian Random Change Point Mixed Model Analysis of Cognitive Performance Trajectories to Identify Eligible Patients for Randomized Clinical Trials
  • CONTRIBUTED SESSION 2 Indigo H (2nd Floor)
    Ethics 1
      Grownish: How And When To Include Adolescents In Adult Research
      Considerations When Collecting Real World Data in Expanded Access Programs
      The Problem of Identifying Vulnerable Research Participants in Pragmatic Cluster Randomized Trials
      Dotting Your I's and Crossing Your T's: An Informed Consent Documentation Tool for Clinical Trials
  • CONTRIBUTED SESSION 3 Indigo 202 A (2nd Floor)
    Operations 1
      Increasing the Generalizability of Pain Study Results
      OlympiA – A Complex but Successful Model for a Large Global Trial
      The Protocol Review Checklist: A Tool to Ensure Protocol Completeness, Consistency, and Accuracy
      Lifestyle Intervention Delivery During the COVID Era
  • CONTRIBUTED SESSION 4 Indigo BCFG (2nd Floor)
    Dose-Finding
      A Unified Decision Framework for Phase I Dose-Finding Designs
      Early Phase Dose-Finding Trials in Virology
      Dose-Finding Based on Feasibility and Late-Onset Toxicity in Adoptive Cell Therapy Trials
      A Biomarker-Based Dose-Finding Design for Immunotherapy
  • CONTRIBUTED SESSION 5 Indigo D (2nd Floor)
    Recruitment & Retention 1
      A Novel Approach Employing Readability Metrics and Crowdsourcing to Improve Randomised Clinical Trial Information Leaflets
      Using Informational Videos to Support Recruitment for Parenting Trials
      A Culturally and Contextually Situated Multimedia Approach to Recruiting, Consenting, and Randomizing a Hard-to-Reach Spanish-Speaking Population for a Randomized Controlled Trial
      Predicting Patients’ Willingness to Participate in Clinical Trials: A Simulation Tool Using Patient Choice Data
  • CONTRIBUTED SESSION 6 Indigo 204 B (2nd Floor)
    Trial Design 1
      TBD
      Randomization Schemes Using Electronic Health Systems to Facilitate Emergency Department-Based Pragmatic Clinical Trials of Public Health Screening Interventions
      Involving Patients in the Design of Randomized Clinical Trials
      Novel Method of Using JavaScript Encoding and QR (Quick Response) Codes in Remotely Managed Randomization of Blinded Studies in Low-Resource Environments
3:30 PM - 4:00 PM
4:00 PM - 5:30 PM
  • TRIAL OF THE YEAR Indigo BCFG (2nd Floor)
    Coming soon
Tuesday, May 17, 2022
8:30 AM - 5:00 PM
  • REGISTRATION Indigo Light Wall (2nd Floor)
9:30 AM - 10:30 AM
  • CONTRIBUTED SESSION 7 Indigo H (2nd Floor)
    Applied 2
      Accounting for Differential Uptake of Treatment-as-Usual in Open-Label RCTs:
      A Comparison of Methods and Illustration in Mental Health Trials
      Quantifying the Impact of Enrichment in Pre-Post Randomized Controlled Clinical Trials
      SuperLearner Enforced Treatment Effect Estimation in Pediatric Trials
      Bayesian Network Enforced Super Learner Treatment Effect Estimation in Clinical Trial: A Proposal and Application
  • CONTRIBUTED SESSION 8 Indigo D (2nd Floor)
    Operations 2
      Implementation of Substudies in Multi-Center Clinical Trials: The Grade Study Experience
      The What, How, When and Who of Sharing Trial Results Summaries with Trial Participants: Stakeholder Informed Guidance from the RECAP Project
      Challenges Implementing a Clustered Randomized Behavioral Clinical Trial in a Community Based Participatory Research Framework
      Advantages, Disadvantages, and Other Considerations for Trials in Cohorts: A Decade In
  • CONTRIBUTED SESSION 9 Indigo E (2nd Floor)
    Cluster Trials
      Estimating Marginal Treatment Effect in Cluster Randomized Trials with Multilevel Missing Outcomes
      A SAS Macro for the Power of Generalized Estimating Equations Analysis of Cluster Randomized Trials with the Application to Stepped Wedge Designs
      Maximin Optimal Cluster Randomized Designs Accounting for Treatment Effect Heterogeneity
      Power Analysis for Stepped Wedge Cluster Randomized Trials with Continuous Co-Primary Endpoints
  • CONTRIBUTED SESSION 10 Indigo 202 A (2nd Floor)
    Mediation & Trial Design 3
      The Good, The Bad and The Hidden Bias in Mediation Analyses of Clinical Trials
      Challenges for Conducting Mediation Analyses in Multi-Arm Trials
      Combining Non-Adherence and Mediation in a Unified Causal Analysis: A Methodological Review and Application to the AVATAR Trial
      The CREID:
      Complementary Randomized Controlled Trial and Real-World Study for Efficacy, Effectiveness, and Implementation Design, with Illustrations of One Published and Two Proposed Large Studies for Sequential and Parallel Designs
  • CONTRIBUTED SESSION 11 Indigo BCFG (2nd Floor)
    Outcomes
      Integrating Patient Values into Clinical Trials Using a Patient-Centered Composite Endpoint:
      A Case Study Using the Control of Hypertension in Pregnancy Study (CHIPS) Trial
      Virtual Clinical Outcome Ascertainment in a Prostate Cancer Treatment Trial
      Challenges of Data Collection for a Fully Remote Clinical Trial with a Multi-Component Outcome: Virtual ELM Pilot Study
      TBD
  • CONTRIBUTED SESSION 12 Indigo 204 B (2nd Floor)
    Trial Design 2
      Landscape of Phase 2 Trials in Alzheimer’s Disease: A Systematic Review of Trial Characteristics
      A Structured Framework for Adaptively Incorporating External Evidence in Sequentially Monitored Clinical Trials
      Multi-Arm Multi-Outcome Clinical Trial Design and Analysis with Bayesian Spike-and-Slab Priors
      How are Progression Decisions Made Following External Randomised Pilot Trials? A Qualitative Interview Study and Framework Analysis
10:30 AM - 11:00 AM
11:00 AM - 12:30 PM
  • INVITED SESSION 11 Indigo BCFG (2nd Floor)
      Clinical Trials of COVID-19 Vaccines: Overcoming the Challenges
  • INVITED SESSION 12 Indigo H (2nd Floor)
      Using a Single IRB for NIH-Funded Multisite Trials
  • INVITED SESSION 13 Indigo 202 A (2nd Floor)
      Perspectives on Real World Data and Evidence Collection Through Expanded Access
  • INVITED SESSION 14 Indigo D (2nd Floor)
      When and How to Use Covariate Adjustment to Improve Precision in Randomized Trials
  • INVITED SESSION 15 Indigo E (2nd Floor)
      Optimizing the Interdisciplinary Design of Adaptive Platform Trials
  • IN-CONFERENCE WORKSHOP 3 Indigo 202 B (2nd Floor)
      Demystifying Statistics in Clinical Trials
12:30 PM - 2:00 PM
  • SCT BUSINESS MEETING Indigo BCFG (2nd Floor)
  • PRESENTATION OF FELLOWS CLASS Indigo BCFG (2nd Floor)
2:00 PM - 3:00 PM
  • CONTRIBUTED SESSION 13 Indigo D (2nd Floor)
    Applied 3
      Accounting for Unequal Cluster Sizes in Designing Cluster Randomized Trials to Detect Treatment Effect Heterogeneity
      Accounting for Correlation Among the Total Events of Composite Outcomes in Cardiovascular Trials
      A Hybrid Approach to Comparing Parallel-Group and Stepped-Wedge Cluster Randomized Trials When There is Uncertainty in the Intra-Cluster Correlation
      Statistical Assessment of Unplanned Crossover Effect in Surgical Trials
  • CONTRIBUTED SESSION 14 Indigo E (2nd Floor)
    Operations 3
      ClinicalTrials.gov Tracking with Do-It-Yourself Application Programming Interface (DIY API)
      Overview of CDER BIMO Compliance and Enforcement
      Modifications to Surgical Procedures: A Scoping Review and Preliminary Framework to Promote Transparent Reporting and Efficient Sharing
      Disseminating Phase I Vaccine Trial Data in a Pandemic to Inform the Scientific Community – mRNA-1273 Phase I Trials
  • CONTRIBUTED SESSION 15 Indigo BCFG (2nd Floor)
    Data Monitoring
      Assessment of a Risk-Based Quality Management Approach to Protocol Deviations - A Data Coordinating Center's Experience
      Dynamically Generating Study Monitoring Reports via Email
      Analysis of Adverse Event and Serious Adverse Event Data from Randomized Controlled Trials
      Data Visualization Approaches to Presenting Harms in Clinical Trials
  • CONTRIBUTED SESSION 16 Indigo 202 A (2nd Floor)
    Historical Controls
      Local Multisource-Exchangeability Model for Adaptive Information Borrowing from Multiple Historical Controls
      A Bayesian Exact Adaptive Platform Design with Continual Reassessment for Trials Utilizing Real World Data
      Dynamic Borrowing from Historical Controls via the Synthetic Prior with Covariates in Randomized Clinical Trials
      Benefits and Risks in Leveraging Historical Control Data in Clinical Trials
  • CONTRIBUTED SESSION 17 Indigo H (2nd Floor)
    Personalized Medicine
      A RSHINY APPLET for Sequential, Multiple Assignment, Randomized Trials with a Time-to-Event Final Endpoint
      Developing and Externally Validating Clinical Dynamic Prediction Joint Models for Localised Prostate Cancer
      Estimating the Impact of Patient Preference in Two-Stage Clinical Trials for Binary Outcomes When Some Patients are Indifferent to Treatment
      Implementing Personalised Treatment Recommendations to Determine Optimal Treatment Decisions Using Data from a Three-Arm Trial When Both Active Treatments Show Positive Results
3:15 PM - 4:45 PM
  • INVITED SESSION 16 Indigo D (2nd Floor)
      A Partnership between Clinical Safety and Statistics for Aggregate Safety Assessment –Year Two
  • INVITED SESSION 18 Indigo BCFG (2nd Floor)
      All for One, One for All: How to Run Multiple Networks of COVID-19 Clinical Trials on a Common Platform Using Bayesian Method
  • INVITED SESSION 19 Indigo H (2nd Floor)
      A Pragmatic Path to Direct Delivery of Drug to Participants
  • INVITED SESSION 20 Indigo E (2nd Floor)
      Dose Optimization in Oncology: Why, When and How
  • IN-CONFERENCE WORKSHOP 4 Indigo 202 B (2nd Floor)
      TrialTree: A Novel Application for Interactive Trial Design
4:45 PM - 5:00 PM
  • BREAK
5:00 PM - 6:30 PM
  • FOUNDERS KEYNOTE LECTURE Indigo BCFG (2nd Floor)
    Dr. Robert Califf, FDA Commissioner
Wednesday, May 18, 2022
7:00 AM - 12:00 PM
  • REGISTRATION Indigo Light Wall (2nd Floor)
8:00 AM - 9:00 AM
  • CONTRIBUTED SESSION 18 Indigo D (2nd Floor)
    Applied 4
      Outcome Variance After Dropout as an Indicator of Missing-Not-At-Random Bias in Randomized Clinical Trials
      Optimality of Testing Procedures for Survival Data in the Non-Proportional Hazards Setting
      How Much is that Data in the Window? A Comparison of Strategies for Analysing Data Recorded Outside Pre-Specified Visit Windows in Randomised Controlled Trials
      The Application of ACCEPT Software in Retrospective Analysis of Specimen Data (SWOG S0500 Translational Medicine Project)
  • CONTRIBUTED SESSION 19 Indigo E (2nd Floor)
    Operations 4
      One Line on a Manuscript: Operationalizing Ecological Momentary Assessment (EMA) in Clinical Trials
      The CURED Framework: A Data-Driven Management Tool to Aid Successful Delivery of Clinical Research Projects
      Effectiveness of Interventions to Share Trial Results with Health Workers and Policymakers: Results of a Systematic Review
      Communicating Overall Results to Trial Participants: The Perspective of Site Staff from the Show RESPECT Study
  • CONTRIBUTED SESSION 20
    Ethics 2 (ON DEMAND)
      Identifying and Examining Ethical Considerations Facing Data Monitoring Committees
      Development of a Core Outcome Set for the Evaluation of Interventions to Enhance Proxy Consent Decisions on Behalf of Adults who Lack Capacity to Consent:
      A Mixed Methods Study (COnSiDER Study)
      Conceptualising ‘Good’ Proxy Consent Decisions for Clinical Trial Participation:
      Implications for the Development of Interventions to Improve the Quality of Proxy Consent
      Unpacking the ‘Black Box of Horrendousness’:
      A Qualitative Study Exploring the Barriers and Facilitators to Conducting Trials Involving Adults Lacking Capacity to Consent
  • CONTRIBUTED SESSION 21 Indigo H (2nd Floor)
    Recruitment & Retention 2
      Retention to pediatric randomized controlled trials during the COVID-19 pandemic: a qualitative study
      Correcting Disparities In Adolescent Access To Medicines By Promoting Age-Inclusive Research
      Participant Retention in Pediatric Randomized Controlled Trials: Systematic Review and Meta-Analysis
      Strategies to Improve Retention in Randomised Trials: A Cochrane Review
  • CONTRIBUTED SESSION 22 Indigo 204 B (2nd Floor)
    Surgical Trials
      Integration of Qualitative Research Into Surgical Trials to Optimise Trial Conduct and Understanding of the Trial Results For Maximal Impact
      A Core Information Set to Guide Early Phase Surgical Research
      The Effects of Preceding Prospective Collaborative Studies (IDEAL Stage 2b) on the Quality and Impact of Subsequent Randomized Controlled Trials (IDEAL Stage 3) Evaluating Surgical Innovations:
      A Systematic Review and Case-Control Study
      Trial Designs to Target the Conditional Average Treatment Effect, with Application to Operating Surgeon Learning Effects in Surgical RCTS
9:00 AM - 9:15 AM
  • BREAK
9:15 AM - 10:45 AM
  • INVITED SESSION 21 Indigo D (2nd Floor)
      Improving Data Quality in Multi-Center Trials:
      Innovative Approaches Utilized within the Wake Forest NCI Community Oncology Research Program Research Base (WF NCORP RB)
  • INVITED SESSION 22 Indigo 202 A (2nd Floor)
      Design and Analysis of Stepped Wedge Cluster Randomized Trials Based on Marginal Models for Discrete and Continuous Outcomes
  • INVITED SESSION 23 Indigo E (2nd Floor)
      Analysis of Complex Time-to-Event Endpoints in Clinical Trials
  • INVITED SESSION 24 Indigo H (2nd Floor)
      Developing Adaptive Trial Designs: A Collaborative Process Balancing Statistical Efficiency with Clinical Importance
10:45 AM - 11:00 AM
  • BREAK
11:00 AM - 12:30 PM
  • INVITED SESSION 25 Indigo D (2nd Floor)
      Bad Bugs in Tough Places – Developing Capacity to Obtain Compelling Evidence in Challenging Environments
  • INVITED SESSION 26 Indigo E (2nd Floor)
      Pharmacokinetics and/or Pharmacodynamics-Informed Dose-Finding Designs
  • INVITED SESSION 27 Indigo H (2nd Floor)
      Accommodating “History Effects” in Long Duration, Multi-Site Clinical Trials to Ensure Relevant and Compelling Evidence
  • INVITED SESSION 28 Indigo 202 A (2nd Floor)
      Rethinking the Inclusion of Research Biopsies in the Design of Clinical Trials
  • INVITED SESSION 29 Indigo 204 A (2nd Floor)
      Planning, Prioritizing, and Conducting Clinical Research in the VA Learning Healthcare System During the COVID-19 Pandemic
  • IN-CONFERENCE WORKSHOP 5 Indigo 202 B (2nd Floor)
      It Takes a Village: Multi-Disciplinary Approach to Designing Stellar Data Collection Forms

Frequently | Asked

Have a question? If you do not find the answer in our most frequently asked questions
below, please reach out to us at info@sctweb.org.

The early registration deadline is April 4, 2022 at Midnight Eastern Time.
Please click here to view the list of qualifying countries.
We request that all online registrations are paid for by credit card through the secure registration form.
All payments must be made in USD ($) to ensure that the full amount is received.
Credit cards are charged in real time at the time the registration is processed.
Yes. We accept Visa, MasterCard and American Express.

To request an Invitation Letter for the SCT Annual Meeting, please send a request to KellyBurns@sctweb.org after you have completed your registration and received a Meeting Confirmation/Receipt. The letter is subject to approval by office staff and will be sent to you by email.

You must be registered for the Annual Meeting to receive a letter.

Please note that is it your responsibility to check the Visa Entry Regulations into the USA. Further information can be found by clicking here.

If you have not received a receipt, please telephone (847) 427-8010 or email registration@sctweb.org.

Conference | Venue

Hotel Accommodations

The SCT Annual Meeting will take place at the San Diego Hilton Bayfront Hotel.

San Diego Hilton Bayfront Hotel
1 Park Boulevard
San Diego, California, 92101, USA

SCT Group Rate:  $259 single / double (+12.5% tax + $.60 per room)

For best availability, make your reservation online at:

The deadline for hotel reservations is Friday, April 22, 2022.

Government rates are also available for qualifying attendees by clicking here https://book.passkey.com/go/SCTGVT. Please note you will be required to verify you qualify for the government rate upon check-in with a valid ID.  Please contact info@sctweb.org for additional information.

City of San Diego COVID Guidelines
SCT’s 2022 Annual Meeting will follow all Guidelines provided by the city which can be found here:
https://www.sandiegocounty.gov/content/sdc/hhsa/programs/phs/community_epidemiology/dc/2019-nCoV/face-coverings.html

Exhibition | Sponsors

If you are interested in becoming a Corporate Sponsor for our Annual Meeting, or for more information on the Sponsorship options available, please download the prospectus here or contact us at info@sctweb.org.

Thank You to Our 2022 Corporate Sponsors!

Janssen Research & Development

Platinum Sponsor

Janssen Research & Development

Our mission is to transform individual lives and fundamentally change the way diseases are managed, interpreted, and prevented. We believe that challenging something is the best way to change it.

Gold Sponsor

Bristol Myers Squibb

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.

Gold Sponsor

Frontier Science Foundation

Frontier Science Foundation is a not-for-profit research organization dedicated to the improvement of data management and statistical quality in clinical trials and medical research.

Gold Sponsor

GW Biostatistics Center

The GW Biostatistics Center has a 47 year history of leadership in practice-changing clinical trials and biostatistical methodology research. Center research has been recognized in reports to the US President and Congress and resulted in over 60 NEJM publications.

Gold Sponsor

Merck

For more than a century, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Today, MSD continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.

Silver Sponsor

Amgen

Amgen strives to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or save lives. In everything we do, we aim to fulfill our mission to serve patients. And every step of the way, we are guided by the values that define us.

Silver Sponsor

Berry Consultants

Berry Consultants is a statistical consulting company specializing in innovative clinical trial design, Bayesian analysis, adaptive clinical trial execution, and simulation software solutions for the pharmaceutical and medical device industry.

Silver Sponsor

Otsuka Pharmaceutical Co., Ltd

Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” In the U.S., Otsuka America Pharmaceutical, Inc. manufactures, markets, and distributes pharmaceuticals and medical devices in the challenging areas of neuroscience, nephrology, and digital health solutions.

Silver Sponsor

University of Wisconsin DCC

The Data Coordinating Center (DCC) is a component of the Clinical Trials Program in the Department of Biostatistics and Medical Informatics at the UW School of Medicine and Public Health. The DCC supports investigator-initiated NIH or industry-sponsored RCTs. We provide expertise in planning, conduct, monitoring, and analysis of clinical trials.

Silver Sponsor

Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) - a rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF.